SCHEMBL1065200

SCHEMBL1065200

CS(=O)(=O)OC1CC(=O)N(c2cccc(C(F)(F)F)c2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 1/20 0.50
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
HSD17B10 Q99714 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CYP1A2 P05177 1/20 0.40
ALDH1A1 P00352 2/20 0.40
GRM5 P41594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4407432 0.81 ADORA2B (0.48) SMN1; SMN2LMNATSHRMAPTNPC1
SCHEMBL1065166 0.80 SMN1; SMN2 (0.45) SMN1; SMN2LMNAMEN1KMT2ATSHR
SCHEMBL4406453 0.79 ADORA2B (0.44) SMN1; SMN2LMNAMEN1KMT2ATSHR
SCHEMBL5827041 0.76 CA12 (0.53) SMN1; SMN2TSHRMAPTNPC1TP53
SCHEMBL10338717 0.76 SMN1; SMN2 (0.54) SMN1; SMN2LMNAMEN1KMT2ATSHR
SCHEMBL9659383 0.75 SMN1; SMN2 (0.51) SMN1; SMN2LMNAMEN1KMT2ATSHR
SCHEMBL1010467 0.74 SMN1; SMN2 (0.50) SMN1; SMN2LMNAMEN1KMT2ATSHR
SCHEMBL1082991 0.73 SMN1; SMN2 (0.49) SMN1; SMN2LMNAMEN1KMT2ATSHR
SCHEMBL10459937 0.73 SMN1; SMN2 (0.51) SMN1; SMN2LMNAMEN1KMT2ATSHR
SCHEMBL13592654 0.73 SMN1; SMN2 (0.51) SMN1; SMN2LMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268641-B1 HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST ADVINUS THERAPEUTICS PVT LTD (IN) 2014-09-03 EP disclosed
US-8252797-B2 Heterocyclic compounds as adenosine receptor antagonist ADVINUS THERAPEUTICS PVT. LTD. (IN) 2012-08-28 US disclosed
EP-2268641-A2 HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST Advinus Therapeutics Pvt. Ltd. (IN) 2011-01-05 EP disclosed
US-20090298744-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST ADVINUS THERAPEUTICS PVT. LTD. (IN) 2009-12-03 US disclosed
WO-2009118759-A2 HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST ADVINUS THERAPEUTICS PVT. LTD., (IN) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298744-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST ADORA2A, ADORA3, ADORA1 SMN1; SMN2 3103/4885LMNA 2164/4885MEN1 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.